Earticle

초록

영어

Background: Sunitinib, commonly used for metastatic renal cell carcinoma (mRCC), often induces hypothyroidism, affecting 27 to 85% of patients. There are clues suggesting an association between sunitinib-induced hypothyroidism and improved survival outcomes. This study aims to identify the predictive factors of sunitinib-induced hypothyroidism and evaluate whether the occurrence of overt or subclinical hypothyroidism predicts tumor outcome in patients with mRCC. Methods: Patients administered to sunitinib for mRCC was included in this retrospective study. Log-rank test and Cox proportional hazards model were conducted to identify predictive factors of hypothyroidism and prognostic factors of progression-free survival (PFS) and overall survival (OS). Results: A total of 156 patients with mRCC treated with sunitinib were included. Predictive factors of sunitinib-induced hypothyroidism were female (odds ratio (OR), 2.77), sunitinib-induced hypertension (OR, 2.99) and dose reduction of sunitinib due to intolerance (OR, 3.57). Sunitinib-induced overt hypothyroidism was a significant prognostic factor in predicting PFS and OS (hazard ratio, 0.38 and 0.23, respectively). Thyroid hormone replacement did not have an influence on PFS and OS. Conclusions: Female patients, patients who experienced sunitinib-induced hypertension and sunitinib dose reduction are at higher risk of hypothyroidism and need close monitoring. Overt hypothyroidism is a strong prognostic factor of sunitinib treatment outcome in mRCC patients and thyroid hormone replacement does not have a negative effect on tumor outcome.

목차

ABSTRACT
Materials and Methods
Study subjects
Study outcomes
Thyroid function assessment
Statistical analysis
Results
Baseline characteristics
Predictive factors of hypothyroidism
Survival Outcomes
Discussion
Conclusion
Conflict of Interest
References

키워드

저자

• Minoh Ko [ College of Pharmacy, Research Institute of Pharmaceutical Sciences & Natural Products Research Institute, Seoul National University ]
• Hyun Jee Kim [ College of Pharmacy, Research Institute of Pharmaceutical Sciences & Natural Products Research Institute, Seoul National University, Department of Pharmacy, Seoul National University Hospital, Seoul 03080, Republic of Korea ]
• In-Wha Kim [ College of Pharmacy, Research Institute of Pharmaceutical Sciences & Natural Products Research Institute, Seoul National University ]
• Tae Min Kim [ Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University, Seoul 03080, Republic of Korea ]
• Jung Mi Oh [ College of Pharmacy, Research Institute of Pharmaceutical Sciences & Natural Products Research Institute, Seoul National University ] Corresponding Author

참고문헌

발행기관

간행물

표지보기 관심저널 등록

• 간행물명

  한국임상약학회지 [Korean Journal of Clinical Pharmacy]

• 간기

  계간

• pISSN

  1226-6051

• 수록기간

  1991~2026

• 등재여부

  KCI 등재

• 십진분류

  KDC 518 DDC 615